Table 1. Patient, transplant and graft characteristics.
| Variable | n | |
|---|---|---|
| Recipient | ||
| Age (years) | Median (range) | 48 (18–74) |
| Gender | Male/female | 58/36 |
| CMV serology | Negative/positive | 48/46 |
| ABO | O/A/B/AB | 40/37/8/9 |
| Disease | Acute leukaemia (AML/ALL) | 47 (34/13) |
| Other (lymp/Mye/MDS) | 47 (27/10/10) | |
| Disease status | Early/other | 46/48 |
| Donor | ||
| Age (years) | Median (range) | 40 (19–72) |
| Gender | Male/female | 64/30 |
| CMV serology | Negative/positive | 64/30 |
| ABO | O/A/B/AB | 41/45/4/4 |
| Recipient/donor | ||
| Gender (R:D) | Male:female/other | 17/77 |
| CMV matching (R:D) | −/−, −/+, +/−, +/+ | 38/10/26/20 |
| ABO matching | Matched/minor/major/bidirectional | 58/18/13/5 |
| HLA matching | Matched/mM HvG/mM GvH/mM Bi | 77/2/3/12 |
| Transplant | ||
| Donor | Sibling/unrelated | 38/56 |
| Conditioning | Myeloablative (CyTBI/BuCy) | 14 (12/2) |
| Reduced intensity (FluMel/FluCy) | 80 (79/1) | |
| Graft | PBSC/BM | 94/0 |
| Alemtuzumab | No/yes | 36/58 |
| PBSC graft | × 106/kg | |
| TNC | Median (range) | 1006 (266–3762) |
| CD34+ | Median (range) | 6.3 (1.1–19.8) |
| CD3+ | Median (range) | 280 (87–801) |
| CD3+CD4+ | Median (range) | 171 (50–694) |
| CD3+CD8+ | Median (range) | 82 (26–248) |
| CD19+ | Median (range) | 62 (13–245) |
| CD3−CD56+ | Median (range) | 35 (8–101) |
| Tregs | Median (range) | 4.7 (0.8–20.6) |
| Tregs/CD4+ T cells | Median (range) | 0.0296 (0.008–0.086) |
Abbreviations: Bi=bidirectional; BuCy=busulphan/cyclophosphamide; CyTBI=cyclophosphamide/TBI; early=CR1, 1st chronic phase or untreated; FluCy=fludarabine/cyclophosphamide; FluMel=fudarabine/melphalan; GvH=graft-versus-host; HvG=host-versus-graft; lymp=lymphoproliferative; mM=mismatched; Mye=myeloproliferative; R:D=recipient:donor; TNC=total nucleated cells; Tregs=regulatory T cells.